Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genmab A/S
Japan adds a batch of new drugs, including Wegovy, to the national health insurance reimbursement tariff, but discussions over Leqembi for Alzheimer’s are still ongoing, with indications that repricing could be possible if demand expands quickly.
Highlights of recent submissions for approval from the Pink Sheet’s US FDA Performance Tracker
Click Therapeutics And Indivior Collaborate On Prescription Digital Therapeutics In Substance Use Disorder
Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.
The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.